Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COGTNASDAQ:IMTXNASDAQ:KROSNASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGTCogent Biosciences$4.88-2.2%$5.51$3.72▼$12.61$555.62M1.911.26 million shs881,190 shsIMTXImmatics$4.56+5.1%$4.47$3.30▼$13.77$554.27M0.87655,232 shs794,302 shsKROSKeros Therapeutics$13.59+0.9%$12.27$9.12▼$72.37$551.96M1.32827,884 shs624,935 shsTNGXTango Therapeutics$1.29-8.2%$1.48$1.03▼$12.02$138.92M1.021.08 million shs778,180 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGTCogent Biosciences-2.73%+6.35%+17.14%-38.70%-32.11%IMTXImmatics-4.82%-5.55%+4.83%-14.40%-60.55%KROSKeros Therapeutics-1.97%-2.11%+10.59%+32.06%-75.06%TNGXTango Therapeutics+6.87%+11.11%-0.71%-43.09%-80.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOGTCogent Biosciences2.3575 of 5 stars4.40.00.00.03.90.00.6IMTXImmatics2.8128 of 5 stars3.64.00.00.03.41.70.0KROSKeros Therapeutics3.3146 of 5 stars4.31.00.00.02.95.00.0TNGXTango Therapeutics1.6425 of 5 stars3.50.00.00.02.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGTCogent Biosciences 2.75Moderate Buy$14.29192.74% UpsideIMTXImmatics 3.20Buy$16.67265.50% UpsideKROSKeros Therapeutics 2.57Moderate Buy$37.00172.26% UpsideTNGXTango Therapeutics 3.00Buy$12.33859.79% UpsideCurrent Analyst Ratings BreakdownLatest TNGX, KROS, IMTX, and COGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025KROSKeros TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$41.00 ➝ $26.005/8/2025KROSKeros TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $25.005/7/2025COGTCogent BiosciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$8.00 ➝ $7.004/14/2025TNGXTango TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/9/2025KROSKeros TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$43.00 ➝ $25.004/1/2025IMTXImmaticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight4/1/2025KROSKeros TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$15.00 ➝ $15.004/1/2025KROSKeros TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/7/2025COGTCogent BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/7/2025COGTCogent BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$17.002/27/2025COGTCogent BiosciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGTCogent BiosciencesN/AN/AN/AN/A$2.30 per shareN/AIMTXImmatics$155.84M3.56N/AN/A$2.88 per share1.58KROSKeros Therapeutics$214.71M2.57N/AN/A$11.09 per share1.23TNGXTango Therapeutics$42.07M3.30N/AN/A$2.48 per share0.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGTCogent Biosciences-$192.41M-$1.84N/AN/AN/AN/A-112.55%-60.44%N/AIMTXImmatics-$104.98M$0.14N/AN/AN/A-47.94%-15.90%-9.38%N/AKROSKeros Therapeutics-$152.99M-$0.18N/AN/AN/A-27,890.94%-41.74%-38.42%5/14/2025 (Estimated)TNGXTango Therapeutics-$101.74M-$1.21N/AN/AN/A-284.42%-49.64%-32.00%N/ALatest TNGX, KROS, IMTX, and COGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KROSKeros Therapeutics$0.1614N/AN/AN/A$62.01 millionN/A5/13/2025Q1 2025IMTXImmatics-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 million5/12/2025Q1 2025TNGXTango Therapeutics-$0.34-$0.36-$0.02-$0.36$6.73 million$5.39 million5/6/2025Q1 2025COGTCogent Biosciences-$0.56-$0.52+$0.04-$0.52N/AN/A5/6/2025Q1 2025KROSKeros Therapeutics-$0.01$3.62+$3.63$3.62$84.62 million$211.25 million3/27/2025Q4 2024IMTXImmatics-$0.03$0.48+$0.51$0.48$16.16 million$15.67 million2/27/2025Q4 2024TNGXTango Therapeutics-$0.32-$0.35-$0.03-$0.35$7.84 million$4.12 million2/26/2025Q4 2024KROSKeros Therapeutics-$1.36-$1.14+$0.22-$1.14$37.32 million$3.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOGTCogent BiosciencesN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGTCogent BiosciencesN/A6.446.44IMTXImmaticsN/A3.983.98KROSKeros TherapeuticsN/A19.0319.03TNGXTango TherapeuticsN/A8.008.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGTCogent BiosciencesN/AIMTXImmatics64.41%KROSKeros Therapeutics71.56%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipCOGTCogent Biosciences5.92%IMTXImmatics3.30%KROSKeros Therapeutics22.90%TNGXTango Therapeutics6.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGTCogent Biosciences80113.86 million103.92 millionOptionableIMTXImmatics260121.55 million115.42 millionOptionableKROSKeros Therapeutics10040.62 million31.23 millionOptionableTNGXTango Therapeutics90108.11 million100.65 millionOptionableTNGX, KROS, IMTX, and COGT HeadlinesRecent News About These CompaniesTango Therapeutics (NASDAQ:TNGX) Posts Earnings Results, Misses Estimates By $0.02 EPSMay 14 at 7:54 AM | marketbeat.comAnalyzing Tango Therapeutics (NASDAQ:TNGX) and Rosetta Genomics (OTCMKTS:ROSGQ)May 14 at 1:21 AM | americanbankingnews.comTango Therapeutics Reports Q1 2025 Financial Results and Updates on TNG462 and Pipeline DevelopmentsMay 14 at 12:55 AM | nasdaq.comTango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 13 at 2:40 AM | finanznachrichten.deTango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 13 at 2:40 AM | finance.yahoo.comTango Therapeutics Extends Cash Runway Amid Clinical ProgressMay 13 at 12:08 AM | tipranks.comTango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue EstimatesMay 12 at 9:15 AM | zacks.comTango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 12 at 7:00 AM | globenewswire.comAnalysts Set Tango Therapeutics, Inc. (NASDAQ:TNGX) PT at $12.33May 12 at 1:25 AM | americanbankingnews.com4,000,000 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Bought by Farallon Capital Management LLCMay 11 at 7:40 AM | marketbeat.comBalyasny Asset Management L.P. Has $10.13 Million Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)May 11 at 5:30 AM | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Buy" by AnalystsMay 11 at 2:12 AM | marketbeat.comTango Therapeutics (TNGX) to Release Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comTango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseMay 5, 2025 | zacks.comBoxer Capital Management LLC Makes New Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX)May 4, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Makes New Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX)May 4, 2025 | marketbeat.comTCG Crossover Management LLC Invests $33.17 Million in Tango Therapeutics, Inc. (NASDAQ:TNGX)May 1, 2025 | marketbeat.comTango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025May 1, 2025 | globenewswire.comNantahala Capital Management LLC Invests $8.67 Million in Tango Therapeutics, Inc. (NASDAQ:TNGX)April 30, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Trims Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX)April 30, 2025 | marketbeat.comWhy Tango Therapeutics, Inc.’s (TNGX) Stock Is Down 5.37%April 29, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNGX, KROS, IMTX, and COGT Company DescriptionsCogent Biosciences NASDAQ:COGT$4.88 -0.11 (-2.20%) As of 04:00 PM EasternCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Immatics NASDAQ:IMTX$4.56 +0.22 (+5.07%) As of 04:00 PM EasternImmatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Keros Therapeutics NASDAQ:KROS$13.59 +0.12 (+0.89%) As of 04:00 PM EasternKeros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Tango Therapeutics NASDAQ:TNGX$1.28 -0.12 (-8.21%) As of 04:00 PM EasternTango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
